Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.
Immunoglobulins (Igs) that bind amyloid beta peptide (Abeta) are under clinical trials for immunotherapy of Alzheimer disease (AD). We have identified IgMs and recombinant Ig fragments that hydrolyze Abeta. Hydrolysis of peripheral Abeta by the IgMs may induce increased Abeta release from the brain. The catalytic IgMs are increased in AD patients, presumably reflecting a protective autoimmune response. Reduced Abeta aggregation and neurotoxicity attributable to the catalytic function were evident. These findings provide a foundation for development of catalytic Igs for AD immunotherapy.
Taguchi
Hiroaki
H
Chemical Immunology Research Center, University of Texas Houston Medical School, Houston, TX 77030, USA.
Planque
Stephanie
S
Nishiyama
Yasuhiro
Y
Szabo
Paul
P
Weksler
Marc E
ME
Friedland
Robert P
RP
Paul
Sudhir
S
D000544:Alzheimer Disease / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D016229:Amyloid beta-Peptides / Q000276:immunology / Q000378:metabolism*; D017151:Antibodies, Catalytic / Q000276:immunology / Q000378:metabolism* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D006868:Hydrolysis; D007075:Immunoglobulin M / Q000276:immunology / Q000378:metabolism*; D007167:Immunotherapy
D016229:Amyloid beta-Peptides; D017151:Antibodies, Catalytic; D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D007075:Immunoglobulin M